Antiviral Potency of HAART Regimens and Clinical Success Are Not Strictly Coupled in Real Life Conditions: Evidence from the MASTER-1 Study

REFERENCES

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Kingsley LA, Rialdo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573–579.
   PubMed Web of Science ®Google Scholar
• Perrin L, Telenti A. HIV treatment failure for HIV resistance in clinical practice. Science. 1998;280:1871–1873.
   PubMed Web of Science ®Google Scholar
• Roberts NA, Craig C, Sheldon J. Resistance and cross resistance with saquinavir and other protease inhibitors: Theory and practice. AIDS. 1998;12:453–460.
   PubMed Web of Science ®Google Scholar
• Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14: 141–149.
   PubMed Web of Science ®Google Scholar
• Carosi G, and the MASTER Study Group. Surrogate mark-ers in naive HIV patients do not correlate with short-term clinical progression in real life: The Italian MASTER-1 Study. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 2191.
   Google Scholar
• Carosi G, Colomba A, Riccio G, and the MASTER Study Group. Is virologic potency the crucial factor in HAART in real life? The Italian MASTER-1 Study. In: Program and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract WePeB4184.
   Google Scholar
• Panel on Clinical Practices for the Treatment of HIV Infec-tion. Guidelines for the Use of Antiretro viral Agents in HIV-Infected Adults and Adolescents. Document available at www.hivatis.org.
   Google Scholar
• Khoo S, Hennessy M, Mulcahy F, et al. Differences in intracellular drug accumulation between protease inhibi-tors. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chicago, IL. Abstract 258.
   Google Scholar
• Teira R, Santamaria JM, Camara del Mar M, et al. A ran-domized comparison of the effectiveness of ritonavir, saquinavir and indinavir. In: Program and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract TuPeB3219.
   Google Scholar
• Moreno A, Perez-Elias MJ, Munoz V, et al. Long-term comparative outcome of indinavir (IDV) vs. nelfinavir (NFV)-based HAART in naive patients in routine clinical practice. In: Program and abstracts of the 40th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 17–20, 2000; Toronto, Canada. Abstract 1523.
   Google Scholar
• Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immuno-logical, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS. 2000;14:1545–1552.
   PubMed Web of Science ®Google Scholar
• Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunological response without decrease in viral load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423–1430.
   PubMed Web of Science ®Google Scholar
• The AVANTI and the INCAS Study Group. Highly active anti-retroviral therapy including protease inhibitors does not confer a unique CD4+ cell benefit. AIDS. 2000;14:1383–1388.
   PubMed Web of Science ®Google Scholar
• Levitz SM. Improvement in CD4+ cell counts despite per-sistently detectable HIV viral load. New Engl J Med. 1998;338:1074–1075.
   PubMed Web of Science ®Google Scholar
• Kauffman D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4+ cell count in HIV-1 infected indi-viduals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723–724.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chroni-cally infected HIV-infected patients: Evidence from the ICONA study. AIDS. 200115: 1–8.
   Google Scholar
• Carpenter CC, Cooper DA, Fischl M, et al. Antiretroviral therapy in adults. Updated recommendations of the Inter-national AIDS Society - USA panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• Murray JS, Elashoff MR, Lacono-Connors LC, Cvetovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804.
   PubMed Web of Science ®Google Scholar
• Delta Coordinating Committee. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS. 1999;13:565–573.
   PubMed Web of Science ®Google Scholar
• HIV Surrogate Markers Collaborative Group. Human Immunodeficiency Virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis. AIDS Res Hum Retroviruses. 2000;12:1123–1133.
   Google Scholar
• Bidwell Goetz M. Editorial response: Discordance between virological, immunologic, and clinical outcomes of therapy with protease inhibitors among human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:1431–1434.
   PubMed Web of Science ®Google Scholar
• Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet. 1998;351:536–537.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, for the EuroSIDA, the French Hospital Data-base and the Swiss Cohort Study Group. Use of observa-tional databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of co-hort studies with randomized trials. AIDS. 1999;13:2075–2082.
   PubMed Web of Science ®Google Scholar
• Schecter M, Struichner CJ, Harrison L. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV progression: Is more necessarily better? AIDS. 1999;13: 97–102.
   PubMed Web of Science ®Google Scholar
• Clerici M, Seminari E, Suter F, et al., for the MASTER Group. Different immunologic profiles characterise HIV in-fection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. AIDS. 2000;14:109–116.
   PubMed Web of Science ®Google Scholar
• Garcia F, Plana M, Vidal C, et al. Dynamic of viral load rebound and immunological changes after stopping effec-tive antiretroviral therapy. AIDS. 1999;13:F79–F86.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound after stopping antiretroviral therapy. AIDS. 1999;13:F59–F62.
   PubMed Web of Science ®Google Scholar
• Lecossier D, Clevel F, Hance AJ, for the CRIV. Improve-ment in CD4+ T-cell counts in spite of virologic treatment failure: Role of thymic output. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic In-fections; January 30-February 2, 2000; San Francisco, CA. Abstract 453.
   Google Scholar
• Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibi-tor-containing regimen. AIDS. 1999;13:669–676.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Martin JN, Grant RM. Delayed immunologic deterioration among patients who virologi-cally fail protease inhibitor-based therapy. In: Program and abstracts of the 7th Conference on Retroviruses and Op-portunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 236.
   Google Scholar